Étiquette : cytosolic excitability

FDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation, Ralph Ellis, 2020

FDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation Ralph Ellis Medscape, August 21, 2020 The US Food and Drug Administration has approved phase one clinical trials for a synthetic cannabinoid drug designed to treat acute respiratory distress syndrome (ARDS), a life-threatening lung condition which may occur in severe cases of the novel coronavirus, Forbes reported. ARDS can be triggered by over-creation of cytokines, proteins which tell the body to produce more inflammation, Forbes said. The drug going to clinical trials, ARDS-003, would “dampen the cytokine release" and prevent development of ARDS, Tetra Bio-Pharma company CEO and chief regulatory officer Guy Chamberland, MD, [...]

Lire la suite

Astrocytes in rapid ketamine antidepressant action, Matjaž Stenovec et al., 2020

Astrocytes in rapid ketamine antidepressant action Matjaž Stenovec, Baoman Li, Alexei Verkhratsky, Robert Zorec Neuropharmacology, 2020, 173, 108158 Doi : 10.1016/j.neuropharm.2020.108158   H I G H L I G H T S • Ketamine inhibits calcium signalling and enhances cAMP production in astroglia. • Ketamine suppresses exocytosis of gliosignalling molecules and Kir4.1. • Ketamine elevates cholesterol content in the plasmalemma specifically in astrocytes. A B S T R A C T Ketamine, a general anaesthetic and psychotomimetic drug, exerts rapid, potent and long-lasting antidepressant effect, albeit the cellular and molecular mechanisms of this action are yet to be discovered. Besides targeting neuronal NMDARs fundamental for synaptic transmission, ketamine affects the [...]

Lire la suite